Suberohydroxamic acid phenyl ester: Phase II started

TetraLogic began an open-label Phase II trial to evaluate once-daily 1%, twice-daily

Read the full 121 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE